Global  

CytoDyn co-ordinates with Mexican Institutes of Health on leronlimab trial for severe coronavirus patients

Proactive Investors Tuesday, 19 May 2020
CytoDyn Inc (OTCQB:CYDY) has announced plans to work with the Mexican National Institutes of Health (NIH) on a trial of leronlimab for severe coronavirus (COVID-19) patients in the country. The initial trial is expected to include about 30 patients, the company said. After that, there is potential for the NIH of Mexico to get involved in the group's two larger coronavirus trials. “The NIH of Mexico is committed to help alleviate human suffering and mortality of Mexican citizens,” CytoDyn CEO Nader Purhassan said in a statement. “The metropolitan area of the Valley of Mexico has a population of approximately 21.5 million people and the contagious nature of COVID-19 is relentless.” READ: CytoDyn unveils further clinical trial plans in bid to fight coronavirus pandemic “We look forward to working with the NIH of Mexico to rapidly commence with the proposed study,” Pourhassan added. “We also believe that this study results, along with the ongoing Phase 2 study, could establish a path for quick approval in Mexico for use of leronlimab in COVID-19 patients.”  The Vancouver, Washington-based company is currently enrolling for a Phase 2b/3 clinical trial for 390 patients. The study is randomized with a 2:1 drug to placebo ratio. It is also enrolling a Phase 2 trial of 75 mild-to-moderate coronavirus patients. The company has been granted more than 60 emergency Investigational New Drug (eIND) authorizations by the US Food and Drug Administration (FDA) and said it plans to provide an update on the patient population later this week.  “We look forward to evaluating leronlimab as a treatment option for patients of COVID-19,” said Gustavo Terán, who leads the Coordinating Commission of National Institutes of Health and High Specialty Hospitals of Mexico, an organization that coordinates the main institutions of medical care and public research in the country."  “We have seen the devastation of this disease on the citizens of Mexico and are looking forward to providing effective treatment options to mitigate the devastation of COVID-19,” Terán added. Contact Andrew Kessel at [email protected] Follow him on Twitter @andrew_kessel
0
shares
ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

Gym owner reopens business after arrest [Video]

Gym owner reopens business after arrest

10News' continuing coverage of the coronavirus pandemic

Credit: ABC 10 News | San Diego     Duration: 01:37Published
Local health departments doing contact tracing to slow spread of COVID-19 [Video]

Local health departments doing contact tracing to slow spread of COVID-19

The Department of Health in Lee County has contacted nearly 4,000 people and are monitoring 2,670 in hopes of slowing the spread of coronavirus.

Credit: FOX 4 Now Florida     Duration: 02:25Published
Gov. Ron DeSantis: Florida Open To Hosting All Sports [Video]

Gov. Ron DeSantis: Florida Open To Hosting All Sports

DeSantis, who is still rolling out the first phase of the state’s economic recovery effort amid the coronavirus pandemic, said Wednesday he will lift restrictions so teams would be welcome to train..

Credit: CBS4 Miami     Duration: 00:34Published

Related news from verified sources

CytoDyn says Novant Health initiates Phase 2b/3 trial with leronlimab for critically ill coronavirus patients

CytoDyn Inc (OTCQB:CYDY), a late-stage biotechnology company, announced Friday that Novant Health is initiating patient enrollment in a Phase 2b/3 trial for...
Proactive Investors

CytoDyn unveils further clinical trial plans in bid to fight coronavirus pandemic

CytoDyn Inc (OTCQB:CYDY) is set to submit a clinical trial design to the US FDA to compare the effectiveness of leronlimab versus remdesivir, and in combination...
Proactive Investors

CytoDyn partner offers free lab testing for coronavirus-linked Childhood Inflammatory Diseases

CytoDyn Inc (OTCQB:CYDY) announced Friday that its diagnostic partner is now offering comprehensive cytokine profiling tests to help physicians better understand...
Proactive Investors


Tweets about this